Letters Drug firm conflicting interests

Radical change, not tweaking, is needed

BMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b5656 (Published 31 December 2009) Cite this as: BMJ 2009;339:b5656
  1. John H Noble Jr, emeritus professor1
  1. 1State University of New York at Buffalo
  1. jhnoble{at}verizon.net

    Lawton makes the case against major reform of the way the pharmaceutical and medical device industry currently does business against Goldacre’s call for the conduct of clinical trials by disinterested third parties to offset the inherent biases of industry sponsored clinical trials.1 2 He dismisses Goldacre’s argument that …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe